Document is current
Any future updates will be listed below
-
Authors
Wu, Yang https://orcid.org/0000-0002-0650-7713
Levy, Aviya L.
Hermanson, Payton
Janappareddi, Abhinav
Wang, Ting
Gonzalez-Chapa, Jorge A. https://orcid.org/0000-0001-5231-2469
Shi, Jia
Shenoi, Susan https://orcid.org/0000-0002-2495-594X
Li, Mengtao https://orcid.org/0000-0003-4252-2889
Zeng, Xiaofeng https://orcid.org/0000-0002-3883-2318
Lood, Christian https://orcid.org/0000-0002-6171-1952
-
Funding
Funding for this research was provided by:
Cure JM Foundation
Myositis Association
- License Information
-
More Information
Article History
Received: 8 August 2025
Revised: 16 December 2025
Accepted: 24 January 2026
First Online: 19 February 2026
Declarations
:
: In accordance with the Declaration of Helsinki, this study is IRB-approved (PIROSTUDY14426) at Seattle Children’s Hospital and accessed through the Juvenile Myositis Seattle Children’s Hospital Biorepository, headed by Dr. Lood and Shenoi, under IRB approval STUDY00003100 (November 9, 2017) and STUDY00003804 (December 21, 2022). Informed consent or assent was obtained from all patients/caregivers as needed.
: Dr. Lood received research funding from Boehringer Ingelheim, Pfizer, Gilead Sciences, Eli Lilly, Redd Pharma, Archon, Neutrolis, and Amytryx. Dr. Lood is a scientific advisor for Citryll and Redd Pharma. Dr. Shenoi has served as a consultant for Cabaletta Bio. The other authors declare no conflict of interest.
: Not applicable.
